Boehringer Ingelheim Pharmaceuticals Micardis Tablets Recall

Why it was recalled

Subpotent Drug

Product description

Micardis Tablets, (telmisartan Tablets) 80 mg, 30 ct. per folding cartons, Rx only, NDC 0597-0041-37), Distributed by: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877

Lot numbers, UPCs & expiration codes

Lot #860412; SEPT 2022

Where it was sold

AR, CO, CT, LA, NC, ND, NH, NJ, OH, PA and PR

What to do if you have this product

Compare the lot number and expiration date on your package with the codes above.
Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
If you have symptoms you think are related, contact your doctor. In an emergency call 911.
Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number: D-0600-2021
Classification: Class II
Status: Terminated
Recall initiated: May 4, 2021
FDA report date: Jun 9, 2021
Quantity: 15,198 bottles (30 tablets per bottle)
Recall type: Voluntary: Firm initiated
Recalling firm: Boehringer Ingelheim Pharmaceuticals, Inc.

Original FDA data

Every field from FDA enforcement report D-0600-2021, exactly as published.

Show all FDA fields

City: Ridgefield
State: CT
Status: Terminated
Country: United States
Event ID: 87856
Address: 900 Ridgebury Rd
Code information: Lot #860412; SEPT 2022
Postal code: 06877-1058
Report date: Jun 9, 2021
Product type: Drugs
Recall number: D-0600-2021
Classification: Class II
Recalling firm: Boehringer Ingelheim Pharmaceuticals, Inc.
Product quantity: 15,198 bottles (30 tablets per bottle)
Termination date: Oct 14, 2021
Reason for recall: Subpotent Drug
Voluntary / mandated: Voluntary: Firm initiated
Product description: Micardis Tablets, (telmisartan Tablets) 80 mg, 30 ct. per folding cartons, Rx only, NDC 0597-0041-37), Distributed by: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877
Distribution pattern: AR, CO, CT, LA, NC, ND, NH, NJ, OH, PA and PR
Recall initiation date: May 4, 2021
Initial firm notification: Letter
Center classification date: May 28, 2021

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0600-2021, published Jun 9, 2021. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: Oct 2, 2026. Content last changed: Oct 2, 2026.

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.